Oncology Intelligence
Focused analysis of global oncology pipelines, immunotherapy breakthroughs, regulatory acceleration pathways and competitive strategy across major pharmaceutical markets.
Oncology remains the largest therapeutic category globally.
Immuno-oncology, ADCs, targeted therapies and combination regimens are redefining competitive positioning.
Chinese HER2 Bispecific Antibody + PD-1 Combination Approved in the U.S. for Gastroesophageal Adenocarcinoma, Advancing to the Forefront of Global Oncology
August 28, 2026
The U.S. FDA approved zanidatamab with tislelizumab and chemotherapy as a first-line treatment option for adults with HER2-positive unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma.
Bone Marrow Protection Throughout Chemotherapy: Trilaciclib Approved for a New Indication, Extending from First-Line to Post-Relapse Treatment
August 27, 2026
China has approved a new indication for trilaciclib in relapsed extensive-stage small cell lung cancer, extending pre-chemotherapy bone marrow protection to Topotecan-containing regimens.
Breaking Through for an Asian Cancer: China’s Innovation Rewrites the Future of Nasopharyngeal Cancer Treatment
August 25, 2026
Izalontamab brengitecan, the world’s first approved bispecific ADC, is opening new treatment possibilities for patients with recurrent or metastatic nasopharyngeal cancer and expanding into other solid tumors.
The 30-Year Chemotherapy Standard Faces a New Challenge: China’s PD-1 Serplulimab Breaks New Ground in Gastric Cancer Treatment
August 25, 2026
ASTRUM-006 explores a chemotherapy-sparing perioperative strategy using China’s PD-1 inhibitor serplulimab in PD-L1-positive resectable gastric cancer.
Sevabertinib for HER2-Mutant NSCLC in China: A New Targeted Treatment Option
August 20, 2026
Sevabertinib offers a new targeted treatment option in China for adults with advanced or metastatic non-squamous NSCLC harboring activating HER2 mutations after prior systemic therapy.
Current Status of Immunotherapy for Bladder Cancer: From BCG to Precision Combination Therapy
August 19, 2026
Explore the current landscape of bladder cancer immunotherapy, from BCG for high-risk NMIBC to PD-1/PD-L1 inhibitors and emerging combination strategies.
Are Women More Prone to Thyroid Cancer? Causes and Prevention Explained
August 17, 2026
Women are diagnosed with thyroid cancer more often than men. Learn why women may have a higher incidence, common symptoms, risk factors, prevention strategies, and current treatment options.
Where Pancreatic Cancer Develops Matters: Understanding Pancreatic Head Cancer vs. Body and Tail Cancer
August 13, 2026
Learn how pancreatic head cancer differs from pancreatic body and tail cancer, including symptoms, diagnosis, surgery, chemotherapy, and the role of molecular testing.
New Progress in First-Line Treatment of HER2-Positive Breast Cancer: Trastuzumab Deruxtecan Plus Pertuzumab Approved
August 13, 2026
Which Pancreatic Cancer Patients May Benefit from Immunotherapy? An Analysis of Biomarkers and Treatment Options
August 12, 2026
Which pancreatic cancer patients may benefit from immunotherapy? Learn how MSI-H, dMMR, TMB, and other biomarkers may help identify patients who could be candidates for immune checkpoint inhibitors.
Colorectal Cancer Immunotherapy: How MSI-H/dMMR Helps Identify Patients Who May Benefit
August 11, 2026
Learn how MSI-H and dMMR testing helps identify colorectal cancer patients who may benefit from immunotherapy, including PD-1 and CTLA-4-based treatment options.
What Are the Targeted Therapy Drugs for Liver Cancer? Common Targeted Drugs and Treatment Options
August 10, 2026
Learn about common targeted therapy drugs for liver cancer, including sorafenib, lenvatinib, regorafenib, cabozantinib, and ramucirumab, their treatment settings, and key factors physicians consider when selecting therapy.
Gastric Cancer Treatment Is No Longer Just About Chemotherapy: How Precision Medicine Is Shaping the Future | A Comprehensive Guide to HER2, CLDN18.2, and FGFR2b
August 07, 2026
Explore how precision medicine is transforming gastric cancer treatment, including HER2, CLDN18.2, FGFR2b, targeted therapies, immunotherapy, and antibody-drug conjugates.
A New Breakthrough in Colorectal Cancer ADC Therapy: Trastuzumab Rezetecan Approved for HER2-Positive Colorectal Cancer in China
August 07, 2026
China has approved Trastuzumab Rezetecan for HER2-positive colorectal cancer after standard chemotherapy failure, providing a new ADC treatment option for patients with advanced disease.
From Targeted Therapy to the ADC Era: Which Lung Cancer Patients Are Suitable for TROP2 ADC Therapy?
August 06, 2026
Learn how TROP2 antibody-drug conjugates (ADCs) are transforming lung cancer treatment, which patients may benefit, and the future prospects of this innovative precision therapy.
How Do ADCs Treat Lung Cancer? Which Patients May Benefit?
August 05, 2026
Learn how antibody-drug conjugates (ADCs) treat lung cancer, the biomarkers involved, approved ADC therapies, and which patients may benefit from these precision oncology treatments.
Understanding Breast Cancer Subtypes: Differences Between Luminal A, Luminal B, HER2-Positive, and Triple-Negative Breast Cancer
August 05, 2026
Learn the differences between Luminal A, Luminal B, HER2-positive, and Triple-Negative Breast Cancer (TNBC), including biomarkers, treatment strategies, prognosis, and advances in precision oncology.
What Targeted Drugs Are Available for NTRK Fusion Brain Tumors? An Overview of Larotrectinib and Entrectinib Applications
August 04, 2026
Learn how NTRK gene fusions drive certain brain tumors and explore the role of Larotrectinib and Entrectinib in precision treatment, molecular diagnosis, and neuro-oncology.
How Effective Is Afatinib for Head and Neck Cancer? Indications, Clinical Efficacy, and Safety Overview
July 30, 2026
Explore how Afatinib works in head and neck squamous cell carcinoma (HNSCC), including its indications, EGFR-targeted mechanism, clinical efficacy, safety profile, and future combination treatment strategies.
Is Head and Neck Cancer Hereditary? A Comprehensive Guide to Genetics, Risk Factors, and Prevention Strategies
July 30, 2026
Learn whether head and neck cancer is hereditary, explore genetic susceptibility, HPV and EBV infections, major risk factors, hereditary syndromes, and practical prevention strategies.